Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Rhea-AI Summary

Nuvectis Pharma (NASDAQ: NVCT) reported 2025 results and program updates. Cash and cash equivalents were $31.6M at year-end, up from $18.5M in 2024, driven by a February 2025 public offering and ATM access. Net loss was $26.4M in 2025 versus $19.0M in 2024. Nuvectis said its Phase 1b monotherapy and osimertinib combination studies of NXP900 are enrolling, a lorlatinib combination is pending, and cash is expected to fund milestones into the second half of 2027.

Positive

• Cash balance increased to $31.6M at December 31, 2025
• Phase 1b NXP900 monotherapy and osimertinib combination studies are enrolling
• Company expects cash runway into the second half of 2027

Negative

• Net loss increased 39% year-over-year to $26.4M in 2025
• Research and development expenses rose 41% to $18.2M in 2025
• One-time license fees of $2.4M contributed to 2025 losses

News Market Reaction – NVCT

+0.46%

1 alert

+0.46% News Effect

On the day this news was published, NVCT gained 0.46%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Cash & equivalents: $31.6M Cash & equivalents: $18.5M Net loss: $26.4M +5 more

8 metrics

Cash & equivalents $31.6M As of December 31, 2025

Cash & equivalents $18.5M As of December 31, 2024

Net loss $26.4M Year ended December 31, 2025

Net loss $19.0M Year ended December 31, 2024

Stock-based compensation $6.0M Included in 2025 net loss

License fees (milestones) $2.4M One-time license fees in 2025 net loss

R&D expenses $18.2M Year ended December 31, 2025

G&A expenses $9.4M Year ended December 31, 2025

Market Reality Check

Price: $9.04 Vol: Volume 69,388 vs 20-day a...

normal vol

$9.04 Last Close

Volume Volume 69,388 vs 20-day average 58,049, indicating slightly elevated trading activity pre-release. normal

Technical Trading above 200-day MA with price 8.74 vs 200-day MA 7.48, showing a prior upward bias.

Peers on Argus

NVCT was down 3.32% pre-release while peers were mixed: AARD and SGMO declined, ...

1 Up

NVCT was down 3.32% pre-release while peers were mixed: AARD and SGMO declined, ACTU and VTYX were modestly positive, and TIL was slightly negative, pointing to stock-specific rather than broad sector-driven dynamics.

Previous Earnings Reports

5 past events · Latest: Nov 04 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 04	Q3 2025 earnings	Positive	-7.5%	Q3 2025 results with NXP900 Phase 1b initiation and strong cash position.
Nov 04	Q3 2025 earnings	Positive	-7.5%	Third-quarter 2025 update featuring NXP900 progress and extended cash runway.
Aug 05	Q2 2025 earnings	Positive	-5.3%	Q2 2025 results with NXP900 Phase 1a completion and $39M proforma cash.
May 06	Q1 2025 earnings	Positive	-4.4%	Q1 2025 update, $29.9M cash post $15.5M financing and Phase 1a data.
Feb 25	2024 annual results	Positive	-5.8%	2024 results with NXP800 orphan status and follow-on offering into 2027.

Pattern Detected

Earnings-related releases have historically been followed by predominantly negative next-day moves, averaging about -6.13%, suggesting a tendency for the stock to sell off around financial updates.

Recent Company History

Over the past year, Nuvectis has repeatedly paired financial updates with clinical progress on NXP900 and NXP800. Prior earnings releases highlighted completion of NXP900 Phase 1a, advancement into Phase 1b, cash runway guidance into 2027, and an orphan drug designation for NXP800. Despite these milestones and strengthened cash balances (e.g., $35.4M as of Sept 30, 2025), the stock typically moved lower after earnings, underscoring a pattern of cautious market responses to financial disclosures.

Historical Comparison

-6.1% avg move · In the past year, NVCT issued five earnings-related updates, which on average saw -6.13% next-day mo...

earnings

-6.1%

Average Historical Move earnings

In the past year, NVCT issued five earnings-related updates, which on average saw -6.13% next-day moves, indicating that financial result announcements have often been met with selling pressure.

Earnings updates have tracked NXP900’s evolution from Phase 1a completion into Phase 1b, while financings and improving cash balances extended operational runway into 2027.

Market Pulse Summary

This announcement combined full-year 2025 financials with an update on NXP900’s Phase 1b program and...

Analysis

This announcement combined full-year 2025 financials with an update on NXP900’s Phase 1b program and combination studies in EGFR‑mutated and ALK‑positive NSCLC. Cash and cash equivalents reached $31.6M, while net loss widened to $26.4M as R&D and G&A expenses increased. Historically, earnings updates have coincided with negative next‑day stock moves averaging -6.13%. Investors may track future readouts from NXP900 Phase 1b and the evolution of annual spending versus available cash runway.

Key Terms

phase 1b, osimertinib, non-small cell lung cancer, nsclc, +3 more

7 terms

phase 1b medical

"Our Phase 1b monotherapy study evaluating NXP900’s clinical potential..."

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

osimertinib medical

"combination study of NXP900 with osimertinib in patients with EGFR-mutated..."

Osimertinib is an oral cancer drug that blocks a specific protein signal driving growth in certain lung cancers, including forms that resisted earlier treatments. Think of it as a specialized key that locks a faulty switch in cancer cells, slowing their spread. For investors, trial results, regulatory approvals, patent life, pricing and competition directly influence sales prospects and the value of companies that develop, license or sell the medicine.

non-small cell lung cancer medical

"osimertinib in patients with EGFR-mutated non-small cell lung cancer (“NSCLC”)..."

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

nsclc medical

"lorlatinib in ALK-positive NSCLC, is pending commencement."

NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.

alk-positive medical

"In addition, a combination with lorlatinib in ALK-positive NSCLC..."

ALK-positive means a cancer has a specific genetic change in the ALK gene that helps the tumor grow. For investors, that status matters because it makes patients eligible for drugs that specifically target that change, which can drive demand, influence clinical trial outcomes and shape the commercial prospects of companies developing those targeted therapies—think of it as a lock-and-key match between a drug and a subgroup of patients.

stock-based compensation financial

"Net loss for the 2025 fiscal year included $6.0 million in non-cash stock-based compensation..."

Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.

at-the-market facility financial

"resulted from the Company's February 2025 public offering and from access to our at-the-market facility..."

An at-the-market facility is a standing arrangement that lets a publicly traded company sell new shares directly into the open market at whatever the current market price is, typically through an investment bank acting as a sales agent. For investors it matters because it provides the company with a flexible way to raise cash without a large, one-time share offering; however, selling additional shares can dilute existing ownership and, by increasing supply, may pressure the stock price like adding more tickets to a limited-seat event.

AI-generated analysis. Not financial advice.

FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the year ended December 31, 2025 and provided an update on recent business progress.

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “2025 was an eventful year for Nuvectis, with significant progress made in the NXP900 development program, laying the groundwork for multiple potential data readouts in 2026. Our Phase 1b monotherapy study evaluating NXP900’s clinical potential in several molecularly and histologically-defined target tumors, and the combination study of NXP900 with osimertinib in patients with EGFR-mutated non-small cell lung cancer (“NSCLC”) are enrolling patients. In addition, a combination with lorlatinib in ALK-positive NSCLC, is pending commencement. With the potential embedded in the NXP900 Phase 1b program, we expect 2026 to be an exciting year for Nuvectis.”

Mr. Bentsur concluded, “We remain focused on operational execution and financial responsibility, and believe that our current cash position can take us through multiple potential NXP900 Phase 1b milestones and well into the second half of 2027.”

Full Year 2025 Financial Results

Cash and cash equivalents were $31.6 million as of December 31, 2025, compared to $18.5 million as of December 31, 2024. The increase of $13.1 million resulted from the Company's February 2025 public offering and from access to our at-the-market facility, partially offset by operating expenses.

The Company's net loss was $26.4 million for the year ended December 31, 2025, compared to $19.0 million for the year ended December 31, 2024, an increase in net loss of $7.4 million. Net loss for the 2025 fiscal year included $6.0 million in non-cash stock-based compensation and one-time license fees associated with milestone achievements of $2.4 million.

Research and development expenses, including non-cash and one-time non-recurring expenses, were $18.2 million for the year ended December 31, 2025, compared to $12.9 million for the year ended December 31, 2024, an increase of $5.3 million.

General and administrative expenses, including non-cash and one-time non-recurring expenses, were $9.4 million for the year ended December 31, 2025, compared to $6.9 million for the year ended December 31, 2024, an increase of $2.5 million.

Finance income was $1.1 million for the year ended December 31, 2025, compared to $0.8 million for the year ended December 31, 2024, an increase of $0.3 million.

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company's assets include NXP900 a clinical-stage drug candidate. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study and the Phase 1b program has been initiated.

For more information on Nuvectis, please visit our website at https://nuvectis.com/ .

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate", "believe", "contemplate", "could", "estimate", "expect", "intend", "seek", "may", "might", "plan", "potential", "predict", "project", "target", "aim", "should", "will", "would", or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward looking statements are based on Nuvectis Pharma, Inc.'s current expectations and interpretations of data and information available, including preclinical and clinical safety, pharmacokinetics, pharmacodynamics, and efficacy data generated to date for NXP900 and the timing and safety and efficacy data expectations for the monotherapy and combination components of the NXP900 Phase 1b program and estimates and projections regarding our financial condition. The outcomes of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties may also be subject to market and other conditions and described more fully in the section titled "Risk Factors" in our 2025 Form 10-K and our other public filings with the U.S. Securities and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com

Media Relations Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

NUVECTIS PHARMA, INC.
BALANCE SHEETS
(USD in thousands, except per share and share amounts)
	December 31,
	2025				2024
Assets
CURRENT ASSETS
Cash and cash equivalents	$	31,634			$	18,533
Other current assets		75				74
TOTAL CURRENT ASSETS		31,709				18,607
TOTAL ASSETS	$	31,709			$	18,607
Liabilities and Shareholders’ Equity
CURRENT LIABILITIES
Accounts payables	$	6,274			$	2,498
Accrued liabilities		115				840
Employee compensation and benefits		6,907				5,556
TOTAL CURRENT LIABILITIES		13,296				8,894
TOTAL LIABILITIES		13,296				8,894
COMMITMENTS AND CONTINGENCIES, see Note 3
SHAREHOLDERS’ EQUITY, see Note 6
Common Shares, $0.00001 par value – 60,000,000 shares authorized as of December 31, 2025, and December 31, 2024, 25,676,798, and 19,495,683 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively		*				*
Additional paid in capital		118,100				82,958
Accumulated deficit		(99,687	)			(73,245	)
TOTAL SHAREHOLDERS’ EQUITY		18,413				9,713
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	31,709			$	18,607
*     Represent amount lower than $1,000 USD.

NUVECTIS PHARMA, INC.
STATEMENT OF OPERATIONS
(USD in thousands, except per share and share amounts)
	For the year ended				For the year ended
	December 31, 2025				December 31, 2024
OPERATING EXPENSES
Research and development	$	18,153			$	12,918
General and administrative		9,421				6,929
OPERATING LOSS		(27,574	)			(19,847		)
Finance income		1,132				847
NET LOSS	$	(26,442	)		$	(19,000		)
EFFECT OF WARRANTS MODIFICATION,		(2,429	)			—
TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS		(28,871	)			(19,000		)
BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING	$	(1.32	)		$	(1.11		)
Basic and diluted weighted average number of common shares outstanding		21,812,716				17,113,169

FAQ

What were Nuvectis (NVCT) year-end cash and cash equivalents for 2025?

Nuvectis reported $31.6 million in cash and cash equivalents at December 31, 2025. According to the company, this increase from $18.5 million was driven by a February 2025 public offering and use of its at-the-market facility.

How did Nuvectis (NVCT) net loss for 2025 compare to 2024?

The company reported a $26.4 million net loss in 2025, up from $19.0 million in 2024. According to the company, the increase includes non-cash stock compensation and one-time license fees tied to milestone achievements.

What is the status of Nuvectis' NXP900 clinical programs for 2026 (NVCT)?

Nuvectis said its Phase 1b monotherapy study and the osimertinib combination in EGFR-mutated NSCLC are enrolling patients. According to the company, a lorlatinib combination in ALK-positive NSCLC is pending commencement with potential multiple 2026 readouts.

How long does Nuvectis (NVCT) expect its cash to fund operations?

The company stated it expects current cash to fund operations through multiple Phase 1b milestones and into the second half of 2027. According to the company, this runway reflects 2025 financing and current operating plans.